DNA

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $17 million…

5 months ago

24/7 Market News: Kraig Labs Positioned at the Forefront of the Next-Gen Materials Revolution

Spider Silk: The Breakthrough Material Powering the Future of Wearable TechDENVER, Sept. 12, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer…

5 months ago

Prenetics Announces Second Quarter 2025 Financial Results with IM8 on Track to Achieve $100M Annual Recurring Revenue by Year’s End

1st Half revenue grew 452.1% to $32.3 million YoY IM8 achieved $5.9 million revenue in August 2025, representing a CAGR1…

5 months ago

DNA-Encoded Library Data: Unlocking Chemomic Insights for Drug Discovery, Upcoming Webinar Hosted by Xtalks

In this free webinar, gain insight into why the majority of DNA-encoded library (DEL) data has historically been ignored, and…

5 months ago

Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio

The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development,…

5 months ago

Bioxodes positive Phase 2a stroke data show breakthrough potential of innovative therapeutic candidate BIOX-101

Safety endpoint met, with encouraging signs of efficacy in trial with 23 patients suffering from intracerebral hemorrhage (ICH)Findings suggest BIOX-101…

5 months ago

Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025

NOTTINGHAM, United Kingdom, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope®…

5 months ago

Exousia Pro Files Provisional Patent for Novel Extracellular Vesicle Loading Method, Tapping into Multi-Billion Dollar Markets

ORLANDO, FL / ACCESS Newswire / September 10, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company and innovator…

5 months ago

Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock

CHICAGO and FORT WORTH, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”),…

5 months ago

Co-Diagnostics, Inc. Honored at Utah Business 2025 Innovation Awards Summit

SALT LAKE CITY, Sept. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with…

5 months ago